Market Insights Snapshot
In Illinois, Avexia has maintained a strong hold in the Capsules and Topical categories, consistently ranking at 2nd and 1st place respectively from July to October 2023. However, the brand has seen a slight decrease in sales in these categories over the same period. Specifically, in the Capsules category, sales dropped from $281,415 in July to $220,320 in October. In the Concentrates category, Avexia has shown substantial improvement, moving from 21st position in July to 15th in October, coupled with an increase in sales. It's worth noting that Avexia's rank in the Tincture & Sublingual category for September and October is missing, which implies that the brand did not make it to the top 20 in this category during these months.
Turning to Maryland, Avexia has shown exceptional performance in the Topical category, securing the 1st position from July to October 2023. The brand also saw a significant increase in sales in this category, from $35,650 in July to $81,621 in October. In the Tincture & Sublingual category, Avexia made a notable jump from 5th place in July to 1st in September, but dropped to 2nd place in October. However, in the Concentrates category, the brand's ranking has been fluctuating, and sales have been decreasing. In Massachusetts and Nevada, Avexia's performance varies across categories with some positive trends observed.
In the Topical category for the state of Illinois, Avexia has consistently maintained its position as the top-selling brand from July to October 2023, outperforming its closest competitors. Doctor Solomon's, despite holding the second rank consistently, has significantly lower sales than Avexia. Similarly, Nature's Grace and Wellness, ranking third, also trails behind Avexia in terms of sales. While Avexia's sales have shown a steady upward trend, Nature's Grace and Wellness experienced a drop in sales in October 2023. This data suggests that Avexia has a strong market presence and is a leading choice for consumers in the Topical category in Illinois.
In October 2023, Avexia's best-selling product was the 'CBD/THC 1:1 Harmony Pain Relief Balm' with 10,457 units sold, maintaining its top position from previous months. The 'CBN/CBD/THC 1:1:1 Comfort Tablets 40-Pack' moved up to the second rank from third in September. The 'CBD/THC 1:1 Harmony Micro-Dosed Tablets 40-Pack' also improved its rank, moving from fourth to third. However, the 'CBD/THC 4:1 Relief Tablets 40-Pack' slipped from second to fourth. The 'CBG/THC 1:1 Ascend Balance Tablets 40-Pack' remained consistent at the fifth position.